Olawale Osuntokun

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 818 citations · Full text

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 815 citations

Randomised Trials, Clinical Trials, Clinical Dermatology +5

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Bruce J. Kinon, Lu Zhang, Brian A. Millen et al. · Journal of Clinical Psychopharmacology · 2011 · 254 citations

Neuropsychology, Active Control Olanzapine, Psychotropic Medication +19

A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder

Michael E. Thase, S. Corya, Olawale Osuntokun et al. · The Journal of Clinical Psychiatry · 2007 · 225 citations

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo et al. · The Journal of Dermatology · 2016 · 190 citations · Full text